Latest Content

Emactuzumab improved tumor response and function in TGCT, showing rapid, durable benefits in a phase 3 trial with a short-course treatment approach.

Dr. Costas Bizekis discusses how minimally invasive surgery is improving recovery, reducing complications and enhancing outcomes in esophageal cancer.

Stage 1 urothelial carcinoma is highly treatable; learn about diagnosis, treatment options and how to reduce recurrence risk through ongoing monitoring.

Meetings like SGO drive collaboration and patient-centered progress, as Dr. Ginger J. Gardner highlights their role in advancing access and research.

Persistent heartburn may signal more than GERD. Learn how reflux can lead to Barrett’s esophagus and increase esophageal cancer risk.

April is Testicular Cancer Awareness Month. Join me this month raising awareness among young men ages 15 to 35 of one the handful of cancers that impacts men before adulthood.

Rezatapopt shows activity in TP53-mutated ovarian cancer, with responses seen across heavily pretreated patient groups and manageable side effects.

Daraxonrasib improved overall survival versus chemotherapy in metastatic pancreatic cancer.

A leukemia survivor shares how her experience inspired a national support network for young adults navigating cancer and survivorship.

Gynecologic oncology is evolving beyond surgery, with greater focus on systemic therapies, team-based care and improved patient outcomes.

Real-world data show ADCs benefit more diverse, older and pretreated patients, helping guide care and build confidence beyond limited clinical trial populations.

Treatment with Verzenio and letrozole may help control advanced or recurrent endometrial cancer for some patients, according to new research.